Clinical Trial Update: A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating FMX103 1.5% topical minocycline foam for facial papulopustular rosacea has completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Facial Papulopustular Rosacea

Drugs mentioned

• FMX103 1.5% topical minocycline foam (minocycline)

Snippet

Sponsor: Vyne Therapeutics Inc. | Conditions: Facial Papulopustular Rosacea | Phase 3 | Status: COMPLETED | Results posted: 2020-12-17